WHO Raises Warning Over Critical Lack of Weight-Loss Injections
Under a tenth of individuals eligible to benefit from obesity jabs such as Wegovy can access them, states the World Health Organization as it releases its inaugural recommendations on the medications.
Considering more than one billion people worldwide now classified as obese, it is urging more widespread and fairer access to these injectable treatments.
According to projections, in excess of 2,000,000,000 could be living with obesity by 2030 without intervention.
"The latest guidance acknowledges that obesity is a chronic disease that can be addressed with thorough and continuous treatment," said its chief Tedros Adhanom Ghebreyesus.
High costs, constrained manufacturing, and distribution challenges are major barriers to universal access to the jabs that can aid individuals in losing significant body mass, explains the body.
GLP-1 Therapy Scarcity
Despite the present best projected outlook, the production of GLP-1 therapies would only suffice for approximately 100 million people – under 10% of eligible patients, according to the health organization.
The guideline encourages governments and firms to widen access, by strategies like licensing agreements.
A patent on the active ingredient – the primary component of a leading brand – is due to expire in a number of countries in 2026.
How Obesity Drugs Function
GLP-1 drugs replicate a natural hormone to slow digestion, suppress the appetite and boost satiety so individuals eat less.
Patients typically start to lose weight in the initial weeks of starting on the weekly injections.
Evidence indicates patients may regain a significant portion a year later of stopping the treatment, as their typical food cravings resume.
To be above a healthy weight increases your risk for contracting diseases, like type 2 diabetes, cardiovascular issues, brain attack, and specific malignancies.
Excess weight affects people in countries worldwide and was associated with millions of deaths worldwide in 2024, according to the health agency.
